Content deleted Content added
now owned by molecular devices |
Citation bot (talk | contribs) m Removed URL that duplicated unique identifier. | You can use this bot yourself. Report bugs here. | User-activated. |
||
Line 3:
[[File:Bio-layer interferometry wavelength shift due to analyte binding .gif|thumb|Figure 3]]
'''Bio-layer interferometry''' ('''BLI''') is a [[label-free]] technology for measuring [[molecular interaction|biomolecular interactions]]<ref>{{cite journal |last1=Cooper |first1=Matthew |title=Current biosensor technologies in drug discovery. |journal=Drug Discovery World |date=May 7, 2006 |issue=Summer |pages=
The binding between a [[Ligand (biochemistry)|ligand]] immobilized on the biosensor tip surface and an analyte in solution produces an increase in [[optical thickness]] at the biosensor tip, which results in a [[wavelength]] shift, Δλ (Figure 3), which is a direct measure of the change in thickness of the biological layer. Interactions are measured in real time, providing the ability to monitor binding specificity, rates of association and dissociation, or concentration, with high precision and accuracy.
Only molecules binding to or dissociating from the biosensor can shift the interference pattern and generate a response profile. Unbound molecules, changes in the [[refractive index]] of the surrounding medium, or changes in flow rate do not affect the interference pattern. This is a unique characteristic of bio-layer interferometry and extends its capability to perform in crude samples used in applications for protein-protein interactions<ref>{{cite journal |last1=Fang |first1=Ye |title=Label-Free Cell-Based Assays with Optical Biosensors in Drug Discovery |journal=Assay and Drug Development Technologies |date=20 November 2006 |volume=4 |issue=5 |pages=
Bio-layer interferometry was pioneered by the founders of [[ForteBio]], an instrument manufacturer based in [[Fremont, California]] which is now part of [[Molecular Devices]].<ref>{{cite web |title=Molecular Devices announces brand identity for its newly-formed biologics business unit |url=https://www.fortebio.com/news_details.html?id=53 |website=www.fortebio.com |accessdate=24 November 2018 |language=en}}</ref>
|